Stockscreener 앱 받기
5.02
0.79%
-0.04
시간 외 거래:
5.12
0.10
+1.99%
Savara Inc 주식(SVRA)의 최신 뉴스
Savara Inc. (SVRA) Reports Q1 Financial Results - Insider Monkey
Savara Inc stock (US80633A1025): fresh IMPALA?2 data at ATS 2026 keeps rare?disease bet in focus - AD HOC NEWS
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 20 - BioSpace
Savara presents biomarker data from molgramostim trial at ATS - Investing.com
Savara (SVRA) Reports New Clinical Findings at ATS 2026 Conferen - GuruFocus
Savara presents biomarker data from molgramostim trial at ATS By Investing.com - Investing.com Canada
Rare lung disease trial: Savara drug cuts biomarkers tied to severity - Stock Titan
SVRA Stock Price, Quote & Chart | SAVARA INC (NASDAQ:SVRA) - ChartMill
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BioSpace
Savara presents 48-week data on molgramostim for rare lung disease - Investing.com Nigeria
SVRA: MOLBREEVI nears approval for aPAP, backed by strong data and robust commercial preparation - TradingView
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - BioSpace
Savara Inc stock (US80633A1025): higher losses, trial progress and elevated short interest - AD HOC NEWS
Savara reports exercise improvements in aPAP drug trial By Investing.com - Investing.com Australia
Savara reports exercise improvements in aPAP drug trial - Investing.com
Is Savara’s Rising Quarterly Loss Reshaping the Risk‑Reward Profile for Investors in SVRA? - simplywall.st
Savara Inc stock (US80633A1025): respiratory disease specialist after latest clinical and funding up - AD HOC NEWS
SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy - Stocktwits
Guggenheim Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
Savara stock (US80633A1025): Rare disease biotech gains 3.74% on trading momentum - AD HOC NEWS
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $16 - Moomoo
Savara Reports First Quarter Financial Results and Provides Business Update - BioSpace
SVRA SWOT Analysis: Key Insights from 10-Q Filing - GuruFocus
Savara (SVRA) Prepares for Commercial Launch with Strong Financi - GuruFocus
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TradingKey - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
Savara Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss - marketscreener.com
Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, Vs. FactSet Est of $-0.13 Loss - Moomoo
Savara Q1 net loss widens on higher R&D costs - TradingView
Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Savara (SVRA) deepens Q1 2026 loss while pushing MOLBREEVI toward key FDA and EMA decisions - Stock Titan
Potential first autoimmune PAP treatment faces Nov. 22 FDA decision - Stock Titan
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference - BioSpace
Swedbank AB Has $5.13 Million Position in Savara Inc. $SVRA - MarketBeat
Nan Fung Trinity HK Ltd. Takes $10.18 Million Position in Savara Inc. $SVRA - MarketBeat
Savara Inc. $SVRA Position Boosted by F m Investments LLC - MarketBeat
SVRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Number of shareholders of Savara, Inc. – NASDAQ:SVRA - TradingView
MSN Money - MSN
Savara faces earnings test ahead of crucial FDA decision By Investing.com - Investing.com South Africa
Savara faces earnings test ahead of crucial FDA decision - Investing.com
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN
Savara Grants Equity Awards to 24 New Employees - MyChesCo
US High Growth Tech Stocks To Watch - Sahm
Savara Inc. ticks higher amid takeover speculation - MSN
2.98%
1.33%
자본화:
|
볼륨(24시간):